Cargando…

Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients

OBJECTIVE: Linc00665 is a novel long non-coding RNA that can promote the progression of breast cancer, but its value in predicting the efficacy of neoadjuvant chemotherapy (NAC) for breast cancer has not been reported. We aim to analyze the correlation between Linc00665 expression and pathological c...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Huijuan, Sheng, Xiaonan, Sha, Rui, Peng, Jing, Yang, Fan, Zhou, Liheng, Lin, Yanping, Xu, Yaqian, Zhang, Shan, Yin, Wenjin, Lu, Jinsong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961084/
https://www.ncbi.nlm.nih.gov/pubmed/33738251
http://dx.doi.org/10.3389/fonc.2021.604319
_version_ 1783665180957212672
author Dai, Huijuan
Sheng, Xiaonan
Sha, Rui
Peng, Jing
Yang, Fan
Zhou, Liheng
Lin, Yanping
Xu, Yaqian
Zhang, Shan
Yin, Wenjin
Lu, Jinsong
author_facet Dai, Huijuan
Sheng, Xiaonan
Sha, Rui
Peng, Jing
Yang, Fan
Zhou, Liheng
Lin, Yanping
Xu, Yaqian
Zhang, Shan
Yin, Wenjin
Lu, Jinsong
author_sort Dai, Huijuan
collection PubMed
description OBJECTIVE: Linc00665 is a novel long non-coding RNA that can promote the progression of breast cancer, but its value in predicting the efficacy of neoadjuvant chemotherapy (NAC) for breast cancer has not been reported. We aim to analyze the correlation between Linc00665 expression and pathological complete response (pCR) in breast cancer patients. MATERIALS AND METHODS: The present study examined the predictive role of Linc00665 expression in pCR after NAC using both univariate and multivariate logistic regression analyses. Receiver operating characteristic (ROC) curve and area under curve (AUC) were utilized to evaluate the performance of Linc00665 in predicting pCR. The Kyoto Encyclopedia of Gene and Genome (KEGG) analysis and Gene Set Enrichment Analysis (GSEA) were also conducted to determine the biological processes where Linc00665 may participate in. RESULTS: The present study study totally enrolled 102 breast cancer patients. The univariate analysis showed that Linc00665 level, human epidermal growth factor receptor 2 (HER2) status and hormone receptor (HR) status were correlated with pCR. The multivariate analysis showed that Linc00665 expression was an independent predictor of pCR (OR = 0.351, 95% CI: 0.125–0.936, P = 0.040), especially in patients with HR-positive/HER2-negative subtype (OR = 0.272, 95% CI: 0.104–0.664, P = 0.005). The KEGG analysis indicated that Linc00665 may be involved in drug metabolism. The GSEA analysis revealed that Linc00665 is correlated to DNA damage repair. CONCLUSION: Linc00665 may be a potential novel predictive biomarker for breast cancer in NAC, especially for HR-positive/HER2-negative patients.
format Online
Article
Text
id pubmed-7961084
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79610842021-03-17 Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients Dai, Huijuan Sheng, Xiaonan Sha, Rui Peng, Jing Yang, Fan Zhou, Liheng Lin, Yanping Xu, Yaqian Zhang, Shan Yin, Wenjin Lu, Jinsong Front Oncol Oncology OBJECTIVE: Linc00665 is a novel long non-coding RNA that can promote the progression of breast cancer, but its value in predicting the efficacy of neoadjuvant chemotherapy (NAC) for breast cancer has not been reported. We aim to analyze the correlation between Linc00665 expression and pathological complete response (pCR) in breast cancer patients. MATERIALS AND METHODS: The present study examined the predictive role of Linc00665 expression in pCR after NAC using both univariate and multivariate logistic regression analyses. Receiver operating characteristic (ROC) curve and area under curve (AUC) were utilized to evaluate the performance of Linc00665 in predicting pCR. The Kyoto Encyclopedia of Gene and Genome (KEGG) analysis and Gene Set Enrichment Analysis (GSEA) were also conducted to determine the biological processes where Linc00665 may participate in. RESULTS: The present study study totally enrolled 102 breast cancer patients. The univariate analysis showed that Linc00665 level, human epidermal growth factor receptor 2 (HER2) status and hormone receptor (HR) status were correlated with pCR. The multivariate analysis showed that Linc00665 expression was an independent predictor of pCR (OR = 0.351, 95% CI: 0.125–0.936, P = 0.040), especially in patients with HR-positive/HER2-negative subtype (OR = 0.272, 95% CI: 0.104–0.664, P = 0.005). The KEGG analysis indicated that Linc00665 may be involved in drug metabolism. The GSEA analysis revealed that Linc00665 is correlated to DNA damage repair. CONCLUSION: Linc00665 may be a potential novel predictive biomarker for breast cancer in NAC, especially for HR-positive/HER2-negative patients. Frontiers Media S.A. 2021-03-02 /pmc/articles/PMC7961084/ /pubmed/33738251 http://dx.doi.org/10.3389/fonc.2021.604319 Text en Copyright © 2021 Dai, Sheng, Sha, Peng, Yang, Zhou, Lin, Xu, Zhang, Yin and Lu http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Dai, Huijuan
Sheng, Xiaonan
Sha, Rui
Peng, Jing
Yang, Fan
Zhou, Liheng
Lin, Yanping
Xu, Yaqian
Zhang, Shan
Yin, Wenjin
Lu, Jinsong
Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients
title Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients
title_full Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients
title_fullStr Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients
title_full_unstemmed Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients
title_short Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients
title_sort linc00665 can predict the response to cisplatin-paclitaxel neoadjuvant chemotherapy for breast cancer patients
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961084/
https://www.ncbi.nlm.nih.gov/pubmed/33738251
http://dx.doi.org/10.3389/fonc.2021.604319
work_keys_str_mv AT daihuijuan linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients
AT shengxiaonan linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients
AT sharui linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients
AT pengjing linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients
AT yangfan linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients
AT zhouliheng linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients
AT linyanping linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients
AT xuyaqian linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients
AT zhangshan linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients
AT yinwenjin linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients
AT lujinsong linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients